Abeona Therapeutics
ABEO
92 hedge funds and large institutions have $585M invested in Abeona Therapeutics in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 12 closing their positions.
112% more call options, than puts
Call options by funds: $9.11M | Put options by funds: $4.3M
68% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 22
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
24% more capital invested
Capital invested by funds: $471M → $585M (+$114M)
5% more funds holding
Funds holding: 88 → 92 (+4)
0.31% more ownership
Funds ownership: 2.78% → 3.09% (+0.31%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$42.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$40M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.4M |
| 4 |
PC
PointState Capital
New York
|
+$10.1M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$27.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$16.4M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$11.9M |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$6.1M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.63M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
101
Tower Research Capital (TRC)
New York
| – | -$74K | -207 | Closed |
|
102
Group One Trading
Chicago,
Illinois
| – | -$31K | -71 | Closed |
|
103
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$4K | -10 | Closed |
|
|
KF
104
Krilogy Financial
St. Louis,
Missouri
| – | -$3K | -8 | Closed |
|
ABEO Hedge Fund Activity: Q2 2018 in Review
92 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q2 2018, worth a combined $585M — up 24% from $471M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ABEO positions and 12 closed out — a net gain of 4 holders — while 37 added to existing stakes and 22 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $42.2M. The largest seller was Citadel Advisors, cutting an estimated $27.9M.
- 92 institutional investors held Abeona Therapeutics (ABEO) as of Q2 2018, up from 88 in Q1 2018.
- Funds reported $585M of Abeona Therapeutics stock for Q2 2018, up 24% quarter-over-quarter.
- 16 funds opened new Abeona Therapeutics positions in Q2 2018 and 12 closed out, a net change of +4 holders.
- The largest Abeona Therapeutics buyer in Q2 2018 was T. Rowe Price Associates, an estimated $42.2M added.
- The largest Abeona Therapeutics seller in Q2 2018 was Citadel Advisors, an estimated $27.9M sold.
Based on aggregated 13F filings for Q2 2018.